TXG
10x Genomics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+49/100
Last price
80.55
▼ 17.19 (17.59%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
98.81
Prev close
97.74
Day high
102.81
Day low
79.90
Volume
9.05M
Market cap
$10.51B
P/E (TTM)
—
52W range
11.16 – 102.81
Day trading desk
Gap from prior close
+5.68%
Prior close 93.50
VWAP
86.11
-6.45% from price
Relative volume
2.83×
Unusually busy
Session range
28.67%
79.90 – 102.81
Position in range
3%
Near session low
ATR (14D)
5.95
7.39% of price
Prior day high
94.56
PDH
Prior day low
88.14
PDL
Bid / ask spread
—
Quote not published
Session volume
8.62M
Avg 3.05M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+10.44%
+8.5%
1M
+54.60%
+53.4%
3M
+158.37%
+153.8%
6M
+346.51%
+328.3%
YTD
+499.26%
+485.0%
1Y
+693.99%
+677.6%
3Y
+136.95%
+54.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on TXG open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-226.12K
Net selling
Buy transactions
8
57.07K shares
Sell transactions
17
283.19K shares
Net transactions
+25
Buys less sells
Sell : buy shares
5.0 : 1
Mixed
Insider-held shares
1.88M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 22, 26 | SAXONOV SERGE WILSON Chief Executive Officer |
SELL | 25.00K | $2.03M | Direct |
| Sep 22, 26 | SULIMAN SHEHNAAZ Director |
SELL | 5.72K | $464.67K | Direct |
| Sep 9, 26 | TAICH ADAM Chief Financial Officer |
SELL | 46.39K | $3.00M | Direct |
| Sep 3, 26 | STUELPNAGEL JOHN R Director |
SELL | 20.00K | $1.24M | Direct |
| Sep 1, 26 | SAXONOV SERGE WILSON Chief Executive Officer |
STOCK | 100 | $0 | Direct |
| Aug 26, 26 | SAXONOV SERGE WILSON Chief Executive Officer |
SELL | 10.49K | $667.90K | Direct |
| Aug 24, 26 | TAICH ADAM Chief Financial Officer |
SELL | 17.17K | $1.08M | Direct |
| Aug 24, 26 | SAXONOV SERGE WILSON Chief Executive Officer |
SELL | 18.55K | $1.17M | Direct |
| Aug 24, 26 | HINDSON BENJAMIN J President |
SELL | 13.82K | $870.86K | Direct |
| Aug 24, 26 | SULIMAN SHEHNAAZ Director |
SELL | 2.21K | $140.48K | Direct |
| Aug 20, 26 | SAXONOV SERGE WILSON Chief Executive Officer |
STOCK | 4.00K | $0 | Direct |
| Aug 14, 26 | TEICHMANN SARAH A. Director |
SELL | 7.55K | $432.28K | Direct |
| Aug 11, 26 | STUELPNAGEL JOHN R Director |
SELL | 20.00K | $1.16M | Direct |
| Jun 22, 26 | SAXONOV SERGE WILSON Chief Executive Officer |
SELL | 30.00K | $1.03M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
HINDSON BENJAMIN J |
President | 488.18K | Sale |
KOSARAJU SRIDHAR |
Director | 68.28K | Stock Award(Grant) |
MATEO ALAN V. |
Director | 85.88K | Stock Award(Grant) |
POPOVITS KIMBERLY J |
Director | 37.45K | Stock Award(Grant) |
SAXONOV SERGE WILSON |
Chief Executive Officer | 1.34M | Sale |
STUELPNAGEL JOHN R |
Director | 328.44K | Sale |
SULIMAN SHEHNAAZ |
Director | 23.79K | Sale |
TAICH ADAM |
Chief Financial Officer | 316.34K | Sale |
TEICHMANN SARAH A. |
Director | 28.06K | Sale |
Fundamentals
Market cap$10.51B
Enterprise value$10.04B
Revenue (TTM)$616.91M
Gross profit$432.53M
EBITDA$-41.20M
Net income$-75.13M
EPS (TTM)$-0.59
Free cash flow$179.66M
Total cash$552.03M
Total debt$78.80M
Book value / share$6.34
Shares outstanding120.21M
Float118.19M
Short % of float18.79%
Dividend yield0.00%
Beta (5Y)1.99
Valuation & profitability ratios
Trailing P/E—
Forward P/E1,052.04
PEG ratio—
Price / sales—
Price / book12.73
EV / revenue16.27
EV / EBITDA-243.59
Gross margin70.11%
Operating margin-15.20%
Profit margin-12.18%
Return on equity-9.40%
Return on assets-5.05%
Debt / equity9.55
Current ratio5.69
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $642.82M | $610.78M | $618.73M | $516.41M | +5.2% |
| Operating revenue | $642.82M | $610.78M | $618.73M | $516.41M | +5.2% |
| Cost of revenue | $198.94M | $196.30M | $209.41M | $120.39M | +1.3% |
| Gross profit | $443.88M | $414.48M | $409.31M | $396.02M | +7.1% |
| Research & development | $238.63M | $264.70M | $270.33M | $265.67M | -9.8% |
| Selling, general & admin | $316.13M | $344.34M | $343.33M | $298.30M | -8.2% |
| Total operating expense | $554.77M | $609.04M | $613.66M | $563.97M | -8.9% |
| Operating income | -$110.89M | -$194.56M | -$204.35M | -$167.94M | +43.0% |
| Net interest income | $20.05M | $18.93M | $16.85M | $6.17M | +5.9% |
| Pre-tax income | -$39.91M | -$177.70M | -$248.76M | -$161.97M | +77.5% |
| Tax provision | $3.64M | $4.93M | $6.34M | $4.03M | -26.2% |
| Net income | -$43.54M | -$182.63M | -$255.10M | -$166.00M | +76.2% |
| Net income to common | -$43.54M | -$182.63M | -$255.10M | -$166.00M | +76.2% |
| Basic EPS | -0.35 | -1.52 | -2.18 | -1.46 | +77.0% |
| Diluted EPS | -0.35 | -1.52 | -2.18 | -1.46 | +77.0% |
| EBIT | -$39.91M | -$177.70M | -$248.73M | -$161.50M | +77.5% |
| EBITDA | $3.91M | -$133.99M | -$205.11M | -$128.49M | +102.9% |
| Basic shares | 124.75M | 120.45M | 117.17M | 113.86M | +3.6% |
| Diluted shares | 124.75M | 120.45M | 117.17M | 113.86M | +3.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $473.97M | $344.07M | $359.28M | $219.75M | +37.8% |
| Cash & short-term investments | $523.41M | $393.40M | $388.69M | $429.98M | +33.0% |
| Accounts receivable | $47.01M | $87.86M | $114.83M | $104.21M | -46.5% |
| Inventory | $56.34M | $83.11M | $73.71M | $81.63M | -32.2% |
| Total current assets | $684.45M | $584.39M | $596.02M | $635.03M | +17.1% |
| Property, plant & equipment | $287.16M | $309.94M | $344.93M | $359.21M | -7.3% |
| Goodwill & intangibles | $66.84M | $20.18M | $21.13M | $27.37M | +231.2% |
| Total assets | $1.04B | $918.64M | $965.14M | $1.03B | +13.4% |
| Total current liabilities | $153.45M | $117.63M | $127.16M | $130.96M | +30.5% |
| Total debt | $84.36M | $82.61M | $95.37M | $95.18M | +2.1% |
| Total liabilities | $245.04M | $208.50M | $224.10M | $223.24M | +17.5% |
| Retained earnings | -$1.51B | -$1.47B | -$1.28B | -$1.03B | -3.0% |
| Shareholder equity | $796.33M | $710.13M | $741.04M | $805.74M | +12.1% |
| Working capital | $531.00M | $466.75M | $468.86M | $504.08M | +13.8% |
| Net tangible assets | $729.49M | $689.95M | $719.92M | $778.37M | +5.7% |
| Shares issued | 127.69M | 122.29M | 119.10M | 115.20M | +4.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$43.54M | -$182.63M | -$255.10M | -$166.00M | +76.2% |
| Depreciation & amortisation | $43.82M | $43.71M | $43.62M | $33.01M | +0.2% |
| Stock-based compensation | $109.12M | $140.75M | $166.95M | $136.85M | -22.5% |
| Change in working capital | $24.94M | $1.25M | $17.34M | -$39.42M | +1,888.8% |
| Operating cash flow | $136.05M | $6.66M | -$15.20M | -$33.61M | +1,941.6% |
| Capital expenditure | -$5.93M | -$13.39M | -$49.52M | -$131.66M | +55.7% |
| Investing cash flow | -$13.44M | -$32.63M | $133.49M | -$350.89M | +58.8% |
| Financing cash flow | $6.80M | $10.91M | $13.67M | $15.82M | -37.7% |
| Free cash flow | $130.12M | -$6.73M | -$64.72M | -$165.27M | +2,033.6% |
| End cash position | $473.97M | $344.07M | $359.28M | $227.35M | +37.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $151.04M | $150.84M | $166.03M | $149.00M | $172.91M | +0.1% |
| Operating revenue | $151.04M | $150.84M | $166.03M | $149.00M | $172.91M | +0.1% |
| Cost of revenue | $38.54M | $44.66M | $52.98M | $48.70M | $47.82M | -13.7% |
| Gross profit | $112.50M | $106.18M | $113.05M | $100.31M | $125.08M | +6.0% |
| Research & development | $56.79M | $56.85M | $55.97M | $57.19M | $61.22M | -0.1% |
| Selling, general & admin | $78.66M | $66.38M | $76.62M | $75.36M | $74.43M | +18.5% |
| Total operating expense | $135.45M | $123.22M | $132.59M | $132.55M | $135.66M | +9.9% |
| Operating income | -$22.95M | -$17.05M | -$19.54M | -$32.24M | -$10.57M | -34.7% |
| Net interest income | $4.80M | $5.01M | $6.89M | $5.20M | $4.27M | -4.3% |
| Pre-tax income | -$18.64M | -$12.85M | -$15.19M | -$28.20M | $37.00M | -45.1% |
| Tax provision | -$714.00K | $623.00K | $1.06M | -$733.00K | $2.46M | -214.6% |
| Net income | -$17.93M | -$13.47M | -$16.25M | -$27.47M | $34.54M | -33.1% |
| Net income to common | -$17.93M | -$13.47M | -$16.25M | -$27.47M | $34.54M | -33.1% |
| Basic EPS | -0.14 | -0.10 | -0.13 | -0.22 | 0.28 | -40.0% |
| Diluted EPS | -0.14 | -0.10 | -0.13 | -0.22 | 0.28 | -40.0% |
| EBIT | -$18.64M | -$17.05M | $51.44M | -$32.24M | $37.00M | -9.4% |
| EBITDA | -$6.96M | -$5.14M | $63.54M | -$19.99M | $46.65M | -35.6% |
| Basic shares | 129.98M | 128.29M | 127.08M | 125.50M | 123.76M | +1.3% |
| Diluted shares | 129.98M | 128.29M | 127.08M | 125.50M | 123.76M | +1.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $502.51M | $490.29M | $473.97M | $432.51M | $397.71M | +2.5% |
| Cash & short-term investments | $552.03M | $539.85M | $523.41M | $482.08M | $447.26M | +2.3% |
| Accounts receivable | $47.55M | $39.03M | $47.01M | $43.78M | $49.98M | +21.8% |
| Inventory | $52.62M | $53.49M | $56.34M | $61.96M | $68.97M | -1.6% |
| Total current assets | $674.67M | $669.73M | $684.45M | $659.83M | $655.66M | +0.7% |
| Property, plant & equipment | $272.01M | $278.98M | $287.16M | $296.18M | $302.41M | -2.5% |
| Goodwill & intangibles | $68.08M | $64.42M | $66.84M | $69.27M | $19.23M | +5.7% |
| Total assets | $1.03B | $1.02B | $1.04B | $1.03B | $979.97M | +1.4% |
| Total current liabilities | $118.51M | $113.60M | $153.45M | $147.32M | $112.22M | +4.3% |
| Total debt | $78.80M | $81.39M | $84.36M | $86.98M | $86.74M | -3.2% |
| Total liabilities | $204.52M | $201.44M | $245.04M | $242.24M | $206.69M | +1.5% |
| Retained earnings | -$1.54B | -$1.52B | -$1.51B | -$1.49B | -$1.47B | -1.2% |
| Shareholder equity | $825.55M | $814.32M | $796.33M | $785.12M | $773.28M | +1.4% |
| Working capital | $556.16M | $556.13M | $531.00M | $512.50M | $543.44M | +0.0% |
| Net tangible assets | $757.47M | $749.90M | $729.49M | $715.85M | $754.05M | +1.0% |
| Shares issued | 130.28M | 128.99M | 127.69M | 126.54M | 124.44M | +1.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$17.93M | -$13.47M | -$16.25M | -$27.47M | $34.54M | -33.1% |
| Depreciation & amortisation | $11.68M | $11.91M | $12.10M | $12.25M | $9.65M | -1.9% |
| Stock-based compensation | $25.62M | $22.64M | $25.22M | $25.26M | $27.56M | +13.1% |
| Change in working capital | -$4.06M | $5.29M | $18.58M | $31.77M | -$53.69M | -176.7% |
| Operating cash flow | $16.97M | $26.12M | $40.78M | $43.21M | $17.71M | -35.0% |
| Capital expenditure | -$1.59M | -$1.60M | -$1.78M | -$687.00K | -$1.58M | +0.6% |
| Investing cash flow | -$7.74M | -$1.31M | -$1.80M | -$8.80M | -$939.00K | -490.0% |
| Financing cash flow | $3.02M | -$8.42M | $2.24M | $617.00K | $3.52M | +135.8% |
| Free cash flow | $15.39M | $24.52M | $39.00M | $42.53M | $16.13M | -37.3% |
| End cash position | $502.51M | $490.29M | $473.97M | $432.71M | $397.71M | +2.5% |
Options analytics
Put / call volume
0.39
Call-heavy session
Put / call open interest
0.66
Positioning, not flow
Max pain
80.00
-0.8% from spot
ATM implied vol
118.3%
Nearest strike to spot
Skew (10% OTM)
-30.3%
Calls bid over puts
Call volume
7.48K
Contracts, this expiry
Put volume
2.95K
Contracts, this expiry
Heaviest call OI
110.00
482 contracts
Heaviest put OI
80.00
475 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.02 | 0.03 | +258.4% |
| Mar 2026 | -0.06 | 0.07 | +219.2% |
| Dec 2025 | -0.04 | 0.07 | +276.3% |
| Sep 2025 | -0.07 | -0.02 | +67.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.02 | 2 | $147.74M | -0.9% |
| Next quarter | -0.01 | 2 | $171.17M | +3.1% |
| Current year | 0.04 | 3 | $620.18M | -3.5% |
| Next year | 0.08 | 3 | $680.93M | +9.8% |
Analyst targets & ownership
Mean target$66.00
High target$110.00
Low target$40.00
Implied upside-18.06%
Analyst count15
ConsensusBUY
Strong buy / Buy1 / 6
Hold12
Sell / Strong sell0 / 0
Held by insiders1.44%
Held by institutions120.32%
Institutions holding524
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
87.50
-7.95% from price
SMA 20
79.64
+22.73% from price
SMA 50
65.83
+48.47% from price
SMA 100
49.92
+61.34% from price
SMA 200
35.16
+178.00% from price
EMA 12
86.55
-6.94% from price
EMA 26
78.18
+3.03% from price
EMA 50
68.30
+17.93% from price
RSI (14)
79.7
Overbought
MACD (12,26,9)
8.38
Hist 1.16
ATR (14)
5.95
6.09% of price
Realised vol 30D
55.6%
Annualised
Bollinger upper
98.66
20, 2σ
Bollinger lower
60.61
20, 2σ
50 / 200 cross
Golden
65.83 vs 35.16
Trend bias
Above 200
+178.00%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.03
Less volatile than market
Correlation to SPY
0.00
Largely independent
Realised vol 30D
55.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-28.0%
Peak to trough
Max drawdown 5Y
-96.1%
Peak to trough
ATR 14
5.95
6.09% of price
Beta (reported)
1.99
5Y monthly, from filing
Short interest
Shares short
16.69M
Prior 15.93M
Change vs prior
+4.8%
Shorts adding
% of float
18.79%
Elevated
% of shares out
12.81%
Against total outstanding
Days to cover
6.2
Crowded exit
Float
118.19M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 29, 26 | Leerink Partners | MAINTAINED | Market Perform | Market Perform |
| Sep 28, 26 | Piper Sandler | MAINTAINED | Neutral | Neutral |
| Sep 28, 26 | Argus Research | INITIATED | — | Buy |
| Sep 9, 26 | UBS | MAINTAINED | Neutral | Neutral |
| Sep 1, 26 | RBC Capital | INITIATED | — | Sector Perform |
| Aug 12, 26 | Stephens & Co. | MAINTAINED | Overweight | Overweight |
| Aug 10, 26 | Piper Sandler | MAINTAINED | Neutral | Neutral |
| Aug 10, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Aug 7, 26 | Citigroup | MAINTAINED | Neutral | Neutral |
| Aug 7, 26 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| Jul 17, 26 | Leerink Partners | MAINTAINED | Market Perform | Market Perform |
| Jul 14, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-08-07
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-06-08
Periodic Financial Reports
10-Q · 2026-05-08
Corporate Changes & Voting Matters
8-K · 2026-05-07
Proxy Statements
DEFA14A · 2026-04-24
Periodic Financial Reports
10-K · 2026-02-13
Corporate Changes & Voting Matters
8-K · 2026-02-12
Headlines
Dow Jones Futures: S&P 500 Hits High As Astera, GE Vernova, Arista Lead Buys, But These Stocks Tumble
Investor's Business Daily · 11m ago
NeoGenomics Sinks 12% on CEO Succession Plan Despite Revenue Beat
TIKR · 8h ago
Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares
Stocktwits · 13h ago
10x Genomics (TXG) Starts Atera Shipments And Sentira, Is The Upside Already Priced In?
Simply Wall St. · 1d ago
Cathie Wood’s ARKG Is Crushing Her Other ETFs: 2 Biotech Bets Have Surged Nearly 6X This Year
Stocktwits · 2d ago
10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises
Zacks · 6d ago
10x Genomics Begins Commercial Shipments of Atera
MT Newswires · 7d ago
10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions
PR Newswire · 8d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.